FDA approves Bluetooth-capable ICD, CRT-D for continuous remote monitoring
Abbott announced that the FDA approved its next-generation Bluetooth-capable implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices.
The devices (Gallant, Abbott) offer Bluetooth connectivity to a patient’s smartphone app for improved remote monitoring and patient/physician engagement, according to a press release from the company.
According to the release, the system pairs with company’s iOS and Android compatible smartphone app (myMerlinPulse, Abbott), which can provide patients with access to data such as device performance and transmission history.
Through the app, physicians can continuously and remotely monitor patients and identify asymptomatic episodes and patient-triggered transmissions, according to the release.
"The ability for patients to stay connected to their doctors via their implanted device and a smartphone app has the potential to change how healthcare providers and patients communicate with each other," Raffaele Corbisiero, MD, FACC, director of electrophysiology and pacing at Deborah Heart and Lung Center, Browns Mills, New Jersey, said in the release. "The FDA’s approval of Abbott’s Gallant devices enables doctors to provide a more collaborative approach to treatment plans and the increased bond between a patient and provider will lead to better outcomes for all."
Collapse